While Medicare Part D coverage has changed, XPHOZAH is available. Learn more
Senior Consultant
Nephrology Associates of Northern Illinois
Oak Brook, IL
President, Desert Kidney Care Co-Director, Eisenhower Medical Center Graduate Medical Education in Nephrology
Rancho Mirage, CA
Assistant Professor of Medicine, Albany Medical College
Albany, NY
Ardelyx, Inc.
Waltham, MA
El Paso Kidney Specialists Clinical Associate Professor of Medicine, Division of Nephrology & Hypertension, Texas Tech University Health Sciences Center
El Paso, TX
Medical Director of Nephrology Services, Great Plains Health Nephrology Medical Director of Outpatient Dialysis, Fresenius Medical Care
North Platte, NE
Physician Partner, Florida Kidney Physicians
Boca Raton, FL
Clinical Professor of Medicine, Morsani College of Medicine Lehigh Valley Hospital Network
Allentown, PA
Chief, Department of Nephrology, UH Ahuja Medical Center
Cleveland, OH
Health Sciences Clinic Professor, Director of Ambulatory Kidney Care Services, Outreach and Innovation, UC Davis School of Medicine
Sacramento, CA
Division of Nephrology, SLU Care Physician Group
St. Louis, MO
Clinical Nephrologist Medical Director, Sutter Health
Palo Alto, CA
Professor of Medicine University of Chicago NorthShore-Endeavor Healthcare
Evanston, IL
South Texas Renal Care Group
San Antonio, TX
XPHOZAH (tenapanor) 30 mg BID is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
XPHOZAH is contraindicated in:
Patients may experience severe diarrhea. Treatment with XPHOZAH should be discontinued in patients who develop severe diarrhea.
Diarrhea, which occurred in 43-53% of patients, was the only adverse reaction reported in at least 5% of XPHOZAH-treated patients with CKD on dialysis across trials. The majority of diarrhea events in XPHOZAH-treated patients were reported to be mild-to-moderate in severity and resolved over time, or with dose reduction. Diarrhea was typically reported soon after initiation but could occur at any time during treatment with XPHOZAH. Severe diarrhea was reported in 5% of XPHOZAH-treated patients in these trials.
For additional safety information, please see full Prescribing Information.
XPHOZAH (tenapanor) 30 mg BID is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
XPHOZAH is contraindicated in:
Patients may experience severe diarrhea. Treatment with XPHOZAH should be discontinued in patients who develop severe diarrhea.
Diarrhea, which occurred in 43-53% of patients, was the only adverse reaction reported in at least 5% of XPHOZAH-treated patients with CKD on dialysis across trials. The majority of diarrhea events in XPHOZAH-treated patients were reported to be mild-to-moderate in severity and resolved over time, or with dose reduction. Diarrhea was typically reported soon after initiation but could occur at any time during treatment with XPHOZAH. Severe diarrhea was reported in 5% of XPHOZAH-treated patients in these trials.
For additional safety information, please see full Prescribing Information.